FMISO-PET with contrast-enhanced MRI

Phase 1Small molecule

FMISO-PET with contrast-enhanced MRI is one of 54 small molecule programs targeting Triple-Negative Breast Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Triple-Negative Breast CancerRecruiting

Triple-Negative Breast CancerPhase 1

Recruiting

Competition

Competitive Landscape

96 competitors in Triple-Negative Breast Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

30 2

Keytruda

Merck & Co.

Phase 3

24 3

Abraxane

Bristol-Myers Squibb

Phase 3

20 4

Trodelvy

Gilead

Phase 3

14 5

Tecentriq

Roche

Phase 3

13 6

Halaven

Eisai

Phase 3

11 7

Paraplatin

AAvyxa

Phase 3

26 8

Gemzar

Johnson & Johnson

Phase 3

8 9

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Imfinzi

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 1Recruiting

Triple-Negative Breast Cancer

NCT04861077

Clinical

Trials by Indication[1]

Triple-Negative Breast Cancer1 trial

Monitoring Breast Cancer Immunotherapy Treatment With Advanced PET/MRI: A Pilot Study

Recruiting·UUniversity of Alabama at Birmingham·Phase 1·NCT04861077·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for FMISO-PET with contrast-enhanced MRI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FMISO-PET with contrast-enhanced MRI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FMISO-PET with contrast-enhanced MRI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Alabama at Birmingham company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Alabama at Birmingham

FMISO-PET with contrast-enhanced MRI

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Triple-Negative Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News